Alterations in the activity of ancient viral DNA that have been incorporated into the human genome may contribute to the development of amyotrophic lateral sclerosis (ALS), according to a study led by researchers at King’s College London. While earlier studies had started to identify connections between these ancient viruses…
Altered activity of ancient viral DNA in human genome tied to ALS
Sponsored Content
A Caregiver’s ALS Journey of Courage and Support
When ALS impacted Rocío's husband Francisco, she knew the disease couldn't shake their greatest source of love and support—their family. Hear how they worked together to get Francisco the understanding and treatment he needed.
Avicenna Biosciences has received its first patent covering new ROCK inhibitor compounds that may be used to treat amyotrophic lateral sclerosis (ALS) and similar disorders. The U.S. patent grants Avicenna exclusive rights to pharmaceutical products containing inhibitors of the Rho associated protein kinases 1 and 2 (ROCK1/2). It also…
Handling night care has been one of the hardest parts about managing ALS for my husband, Todd, but now I’m hopeful because he’s been training himself to sleep on his back. Todd has been a side sleeper, and for years he had to be turned from side to side…
Long-term treatment with the cell therapy NurOwn (debamestrocel) was found to significantly extend survival in people with amyotrophic lateral sclerosis (ALS) when compared with a matched control group from previous clinical trials, according to new data. That data, from an expanded access program (EAP), was shared by NurOwn’s…
Neurosense Therapeutics will meet with the U.S. Food and Drug Administration (FDA) Nov. 6 to discuss plans for a Phase 3 trial to test its experimental therapy PrimeC in amyotrophic lateral sclerosis (ALS). The company said it will give an update on results of the Type C meeting following…
Hmmmmm. That’s what my body feels when it’s doing its “humming thing.” It’s an all-over buzzy sensation that I chalk up to being another quirky symptom of my ALS. It’s a feeling I’ve never mentioned during my ALS clinic visits, mainly because I want to keep the visit rolling along…
A database integrating long-term respiratory data with natural history data from people with amyotrophic lateral sclerosis (ALS) has been made available to scientists globally, with the hopes of accelerating research and the discovery of new therapies. Developed under a collaboration between the nonprofit Target ALS and Zephyrx, the…
Woolsey Pharmaceuticals has received three new U.S. patents covering innovations related to Bravyl (oral fasudil), its investigational amyotrophic lateral sclerosis (ALS) medication. The patents cover the use of oral fasudil to slow the progression of sporadic ALS, as well as solid and liquid formulations of fasudil for people…
A few weeks after my late husband, Jeff, was diagnosed with ALS in 2018, we were sitting in our primary care doctor’s office to talk. We’d just received a second opinion confirming the diagnosis, and we were reeling. I remember how brutal the appointment felt for all three of us.
Recent Posts
- Developers expand collaboration to test 2 novel targets for ALS treatments
- Trial testing new ALS gene therapy starts dosing patients in Australia
- In life with ALS, we find moments of ‘genius’ to keep our minds active
- Brain imaging agent shows promise for detecting toxic ALS protein
- I reframed my life with ALS by becoming a calmer duck